AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
Merck's Keytruda fails in first line bladder cancer
Royalty Pharma plans largest IPO of year so far
Digital health predicted as new normal in COVID aftermath
please scroll down for all the latest news*
